Jokanović Milan, Kosanović Melita, Brkić Dejan, Vukomanović Predrag
Faculty of Medicine, University of Nish, Nish, Serbia.
Clin Neurol Neurosurg. 2011 Jan;113(1):7-10. doi: 10.1016/j.clineuro.2010.08.015. Epub 2010 Sep 28.
About 80 years have passed since the first cases of organophosphate induced delayed polyneuropathy (OPIDP), as the consequence of human poisoning with certain organophosphorus compounds, were described in the literature. OPIDP is a relatively rare neurodegenerative disorder in humans characterized by loss of function, ataxia and paralysis of distal parts of sensory and motor axons in peripheral nerves and ascending and descending tracts of spinal cord appearing 2-3 weeks after exposure or later. The molecular target for OPIDP is considered to be an enzyme in the nervous system known as neuropathy target esterase (NTE). This review discusses OPIDP in man with emphasis on clinical presentation, pathogenesis, molecular mechanisms, and possibilities for prevention/therapy.
自文献中首次描述因某些有机磷化合物中毒导致人类出现有机磷酸酯诱导的迟发性多发性神经病（OPIDP）以来，大约80年过去了。OPIDP是一种相对罕见的人类神经退行性疾病，其特征为功能丧失、共济失调以及外周神经感觉和运动轴突远端部分以及脊髓上下行束在接触后2 - 3周或更晚出现麻痹。OPIDP的分子靶点被认为是神经系统中的一种酶，即神经病变靶标酯酶（NTE）。本综述讨论了人类的OPIDP，重点关注临床表现、发病机制、分子机制以及预防/治疗的可能性。
